Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.

Patel, MN; Patel, AJ; Nandpal, MN; Raval, MA; Patel, RJ; Patel, AA; Paudel, KR; Hansbro, PM; Singh, SK; Gupta, G; Dua, K; Patel, SG

Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.

Patel, MN Patel, AJ Nandpal, MN Raval, MA Patel, RJ Patel, AA Paudel, KR Hansbro, PM Singh, SK Gupta, G Dua, K

Patel, SG

Permalink

Publication Type:: Journal Article
Citation:: Naunyn Schmiedebergs Arch Pharmacol, 2024
Issue Date:: 2024-10-08

Closed Access

	Filename	Description	Size
	Drug Resistant Tuberculsosis_Landscape.pdf	Published version	1.97 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Patel, MN
dc.contributor.author	Patel, AJ
dc.contributor.author	Nandpal, MN
dc.contributor.author	Raval, MA
dc.contributor.author	Patel, RJ
dc.contributor.author	Patel, AA
dc.contributor.author	Paudel, KR
dc.contributor.author	Hansbro, PM
dc.contributor.author	Singh, SK
dc.contributor.author	Gupta, G
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Patel, SG
dc.date.accessioned	2024-10-10T14:01:00Z
dc.date.available	2024-09-17
dc.date.available	2024-10-10T14:01:00Z
dc.date.issued	2024-10-08
dc.identifier.citation	Naunyn Schmiedebergs Arch Pharmacol, 2024
dc.identifier.issn	0028-1298
dc.identifier.issn	1432-1912
dc.identifier.uri	http://hdl.handle.net/10453/181379
dc.description.abstract	Drug-resistant tuberculosis (DR-TB) represents a pressing global health issue, leading to heightened morbidity and mortality. Despite extensive research efforts, the escalation of DR-TB cases underscores the urgent need for enhanced prevention, diagnosis, and treatment strategies. This review delves deep into the molecular and genetic origins of different types of DR-TB, highlighting recent breakthroughs in detection and diagnosis, including Rapid Diagnostic Tests like Xpert Ultra, Whole Genome Sequencing, and AI-based tools along with latest viewpoints on diagnosis and treatment of DR-TB utilizing newer and repurposed drug molecules. Special emphasis is given to the pivotal role of novel drugs and discusses updated treatment regimens endorsed by governing bodies, alongside innovative personalized drug-delivery systems such as nano-carriers, along with an analysis of relevant patents in this area. All the compiled information highlights the inherent challenges of current DR-TB treatments, discussing their complexity, potential side effects, and the socioeconomic strain they impose, particularly in under-resourced regions, emphasizing the cost-effective and accessible solutions. By offering insights, this review aims to serve as a compass for researchers, healthcare practitioners, and policymakers, emphasizing the critical need for ongoing R&D to improve treatments and broaden access to crucial TB interventions.
dc.format	Print-Electronic
dc.language	eng
dc.relation.ispartof	Naunyn Schmiedebergs Arch Pharmacol
dc.relation.isbasedon	10.1007/s00210-024-03466-0
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences, 1116 Medical Physiology
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.title	Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.
dc.type	Journal Article
utslib.location.activity	Germany
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1116 Medical Physiology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)/Associate Member
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Research Consortium in Complementary and Integrative Medicine (ARCCIM)
utslib.copyright.status	closed_access	*
dc.date.updated	2024-10-10T14:00:55Z
pubs.publication-status	Published online

Abstract:

Drug-resistant tuberculosis (DR-TB) represents a pressing global health issue, leading to heightened morbidity and mortality. Despite extensive research efforts, the escalation of DR-TB cases underscores the urgent need for enhanced prevention, diagnosis, and treatment strategies. This review delves deep into the molecular and genetic origins of different types of DR-TB, highlighting recent breakthroughs in detection and diagnosis, including Rapid Diagnostic Tests like Xpert Ultra, Whole Genome Sequencing, and AI-based tools along with latest viewpoints on diagnosis and treatment of DR-TB utilizing newer and repurposed drug molecules. Special emphasis is given to the pivotal role of novel drugs and discusses updated treatment regimens endorsed by governing bodies, alongside innovative personalized drug-delivery systems such as nano-carriers, along with an analysis of relevant patents in this area. All the compiled information highlights the inherent challenges of current DR-TB treatments, discussing their complexity, potential side effects, and the socioeconomic strain they impose, particularly in under-resourced regions, emphasizing the cost-effective and accessible solutions. By offering insights, this review aims to serve as a compass for researchers, healthcare practitioners, and policymakers, emphasizing the critical need for ongoing R&D to improve treatments and broaden access to crucial TB interventions.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181379